RECENT NEWS

My Pathomation's newest release focuses on promoting grassroot initiatives in digital pathology. Anybody can sign up for a free account and get involved with digital pathology this way. Users now upload and tag theirs slides, share them as public collections, or produce online course content within their own organisation.

The digital pathology platform will improve collaboration across the hospital's multi-site network and lay the foundation for unlocking new diagnostic insights with AI.

Takara Bio Europe (TBE) has announced a new partnership with the German company BioeXsen GmbH for the distribution of in vitro diagnostic solutions for the qPCR detection of common pathogens found in respiratory tract infections.

The latest version of Galen transforms diagnosis of prostate, breast and gastric cancer and includes expanded detection, user interface, and workflow integration capabilities.

The Tissue-Tek Genie provides optimal slides with the same turnaround time, using one protocol and achieving optimal staining quality across the entire 130+ Sakura antibody portfolio.

Leica Biosystems, a cancer diagnostics company and a global leader in workflow solutions, and Indica Labs, the industry-leading provider of computational and image management software in digital pathology, have announced a partnership focused on delivering compatible digital pathology workflow solutions.

Global Access Diagnostics (GADx) has acquired the manufacturing rights for the IT-LEISH rapid diagnostic test for visceral leishmaniasis from Bio-Rad, a global leader in life science research and clinical diagnostic products.

Book now for the British Association for Cytopathology (BAC) Annual Scientific Meeting (ASM) 2022, which will take place on 17 September, via Zoom.

The Microbiology Society has announced Daniel Morse (Co-founder of Show Me The Science, and lecturer at the University of Bristol) as the winner of the 2022 Microbiology in Society Award, for his engagement project ‘Show Me The Science’.

Fujifilm Europe will be attending this year’s European Congress of Pathology (ECP) where the Medical Informatics team will be showcasing Inspirata’s Dynamyx software.

Pathologists who used Ibex’s Galen Breast for cancer diagnosis obtained very high accuracy in a multi-site clinical study.

Bruker Corporation has launched its new nanoElute 2 nano-LC platform, which supports fluxomics, as well as the latest advances in PaSER’s intelligent acquisition to enhance research in protein-protein interactions (PPIs) and metaproteomics applications.

Indica Labs, an industry leader in quantitative digital pathology and image management solutions, and The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics (iCAIRD), are to collaborate on the development of an AI-based digital pathology solution for the detection of cancer within lymph nodes from colorectal surgery cases at Greater Glasgow and Clyde NHS.

The evolving strategic relationship will drive the use of artificial intelligence (AI)-powered pathology in translational research and clinical trials.

Biocytogen has entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice platform.

Designed for laboratories performing highly sensitive and precise DNA and RNA analysis in areas such as oncology and infectious diseases, the Digital LightCycler System is a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient’s condition.

The new state-of-the-art facility in Plainville, Massachusetts will be manufacturing materials central to production of gene-based therapeutics.

The new collaboration will create an auto-sampling workflow to reduce errors and accelerate analysis.

The Microbiology Society has announced the finalists of the 2022 Sir Howard Dalton Young Microbiologist of the Year competition.

The global molecular diagnostics market size is expected to reach USD 50.94 Billion in 2030 and register a revenue CAGR of 12.4% over the forecast period, according to the latest report. The rising prevalence of infectious diseases and cancer is anticipated to fuel demand for molecular diagnostic tests.